How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,911 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. eUpdate: Hepatocellular Carcinoma Algorithms

Testicular Germ Cell CancerCancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma Gynaecological Cancers Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer • Ovarian Cancer Haematological Malignancies Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed mantle cell lymphoma • Multiple (...) marginal zone lymphoma of MALT type Head and Neck Cancers Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck Hereditary Syndromes Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes Lung and Chest Tumours Early and locally advanced non-small-cell lung cancer • Metastatic non-small-cell lung cancer • Thymic epithelial tumoursMalignant pleural mesothelioma • Small-cell lung cancer Melanoma Cutaneous Melanoma Neuro-Oncology EANO

2020 European Society for Medical Oncology

282. eUpdate: Hepatocellular Carcinoma Treatment Recommendations

carcinoma Genitourinary Cancers Testicular Germ Cell CancerCancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma Gynaecological Cancers Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer • Ovarian Cancer Haematological Malignancies Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed (...) in adult patients • Gastric marginal zone lymphoma of MALT type Head and Neck Cancers Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck Hereditary Syndromes Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes Lung and Chest Tumours Early and locally advanced non-small-cell lung cancer • Metastatic non-small-cell lung cancer • Thymic epithelial tumoursMalignant pleural mesothelioma • Small-cell lung cancer Melanoma Cutaneous

2020 European Society for Medical Oncology

283. Upper Urinary Tract Urothelial Cell Carcinoma

. 19. Shariat, S.F., et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol, 2011. 29: 481. 20. Roupret, M., et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol, 2008. 54: 1226. 21. Audenet, F., et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according (...) , J.D., et al., TNM Classification of Malignant Tumours. 8th ed. 2016. 53. Roscigno, M., et al. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. BJU Int, 2012. 110: 674. 54. Park, J., et al. Reassessment of prognostic heterogeneity of pT3 renal pelvic urothelial carcinoma: analysis in terms of proposed pT3 subclassification systems. J Urol, 2014. 192: 1064. 55. Lopez-Beltran A. et al. Tumours of the Urinary

2019 European Association of Urology

284. Primary Urethral Carcinoma

for genital preservation in localised and locally advanced tumours; the prognostic impact of neoadjuvant and adjuvant treatment modalities in locally advanced disease; the prognostic impact of the extent of transurethral resection of the prostate prior to bacillus Calmette-Guérin (BCG) treatment in urothelial malignancies of the prostatic urethra and ducts; the therapeutic benefit and clinical safety of programmed cell death (ligand)-1 inhibitors for the treatment of advanced primary urethral carcinoma (...) /TNM) staging system In men and women, urethral carcinoma is classified according to the 8 th edition of the TNM classification [ ] (Table 4.1). It should be noted that there is a separate TNM staging system for prostatic UC [ ]. Of note, for cancers occurring in the urethral diverticulum, stage T2 is not applicable as urethral diverticula are lacking peri-urethral muscle [ ]. Table 4.1: TNM classification (8 th edition) for urethral carcinoma [ ] T - Primary Tumour TX Primary tumour cannot

2019 European Association of Urology

285. Renal Cell Carcinoma

in Europe. BJU Int, 2008. 101: 949. 13. King, S.C., et al. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol, 2014. 191: 1665. 14. Hidayat, K., et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens, 2017. 35: 1333. 15. Lotan, Y., et al. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial (...) and survival in renal cell carcinoma. Eur Urol, 2003. 44: 226. 42. Rathmell, W.K., et al. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Urology, 2008. 72: 659. 43. Hora, M., et al. Tumours in end-stage kidney. Transplant Proc, 2008. 40: 3354. 44. Neuzillet, Y., et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general

2019 European Association of Urology

286. Under-stage and Overlook of Peritoneal Spread from Bladder Urothelial Carcinoma Full Text available with Trip Pro

Under-stage and Overlook of Peritoneal Spread from Bladder Urothelial Carcinoma Bladder cancer can spread from the sub-peritoneal space superior and posterolateral to the peritoneal cavity via the peritoneal lining. The aim of this study was to improve the identification of peritoneal spread from bladder urothelial carcinoma based on computed tomography (CT) scans.This is a retrospective study including patients selected with the following criteria: (i) pathology-confirmed urothelial carcinoma (...) included the abdominal wall in 101 patients (70%), bowel/mesentery in 84 (53%), prostate, uterus, and rectum in 30 (19%), and circumferential tumors that outlined the whole bladder wall in 59 (37%). Initial modes of therapy were chemotherapy in 86 patients (54%), cystectomy in 55 (35%), CCRT in eight (5%), radiotherapy in two (1%), and no therapy in eight (5%). Peritoneal spread due to under-staging (clinical/pathological stage) after local therapy was found in 84 patients (53%).Initial pre-therapeutic

2018 In Vivo

287. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer

in this health technology assessment includes treatment-naïve men with stage I-II localized prostate cancer who undergo definitive monotherapy with CyberKnife SBRT. Clinical Alternatives: Prostate cancer treatment is guided by the initial disease risk category. Options include active surveillance or watchful waiting, radical prostatectomy, external beam radiation therapy using 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy; high-dose-rate brachytherapy; high-intensity-focused (...) resonance image study to outline the prostate gland and fiducials. The CyberKnife computer-controlled robot slowly moves around the patient to deliver radiation from 150 to 300 angles. Five or fewer treatments, each lasting 30 to 90 minutes, are required. Patient Population: CyberKnife has been used in patients with previously untreated, localized stage I to II prostate cancer, and in previously treated patients with advanced or recurrent prostate cancer. The patient population under consideration

2017 Health Technology Assessment (HTA) Database.

288. Magnetic resonance imaging-guided in-bore biopsy for prostate cancer

provide accurate diagnostic and/or staging information for men with suspected or diagnosed prostate cancer? Does use of MRI-IB biopsy improve patient management or outcomes? Is MRI-IB biopsy safe? Have definitive patient selection criteria been established for MRI-IB-biopsy? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Biopsy; Humans; Magnetic Resonance Imaging; Male; Prostatic Neoplasms Language Published English Country of organisation (...) , Inc. Directory Publication. 2017 Authors' conclusions Rationale: Targeted magnetic resonance imaging (MRI)-guided biopsy techniques, such as MRI-guided in-bore (MRI-IB) biopsy, have been developed to increase identification of clinically significant prostate cancer without increasing the detection of clinically nonsignificant tumors. Technology Description: MRI-IB biopsy is a technique that uses MRI images captured in real time and processed by interventional planning software to help insert

2017 Health Technology Assessment (HTA) Database.

289. Prolaris gene expression assay for assessing long-term risk of prostate cancer progression

was associated with a 2.02-fold increase in the hazard of dying from prostate cancer (? 2 =37.6, p=8.6×10 -10 , 95% CI 1.62 to 2.53). The 10-year death rate from prostate cancer was: 19.3% for CCP score 3. The multivariate analysis showed that extent of disease, age, clinical stage and use of hormone therapy were not statistically significant and therefore only CCP score, Gleason score and PSA level remained in the analysis. Multivariate analysis hazard ratio for CCP score was 1.65 (95% CI 1.31 to 2.09, p (...) cancer. The Prolaris score is combined with patient and tumour information to generate either the 10-year prostate cancer-specific mortality risk (from biopsy samples) or the 10-year risk of biochemical recurrence (from prostatectomy specimens), which may indicate the need for further treatment. The Prolaris score would be used in addition to existing risk stratification information and is likely to be used in place of available nomograms, where these are used. Effectiv Effectiveness and safety eness

2016 National Institute for Health and Clinical Excellence - Advice

290. Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage. (Abstract)

to pathological stage of prostate tumours. • Additionally, T21 was associated with Gleason grade and prostate-specific antigen recurrence, although statistical significance was not reached in this restricted cohort of patients.• Taken together these results show that T21 is a potential new biomarker for advanced disease and that elevated levels of T21 appear relevant to prostate cancer development.© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. (...) Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage. • To define the expression pattern of the tumour antigen T21 at the protein level in prostate tissues, prostate cell lines and a panel of normal tissues. • To correlate the expression pattern of T21 in prostate cancer with clinical parameters.• Tissue samples were collected from 79 patients presenting at clinic with either prostate cancer (63 patients) or benign prostatic hyperplasia

2012 BJU international

291. Population-based study of the incidence and survival for intraductal carcinoma of the prostate. (Abstract)

of extraprostatic stage, pT3/T4, 45.9% vs. 21.6% (P<0.001), higher grade, GS≥ 7, 79.3% vs. 62.7% (P<0.001), lymph node metastases, 5.8% vs. 2.4% (P<0.001), and positive surgical margins, 25.6% vs. 19.5% (P = 0.02). IDC-P was associated with a 3-fold increase in prostate cancer-specific mortality relative to non-IDC-P (hazard ratio = 3.0, 95% CI: 1.5-5.7; P<0.01). Limitations include retrospective design and potential underreporting of IDC-P that leads to underestimation of the true effect size.The significance (...) Population-based study of the incidence and survival for intraductal carcinoma of the prostate. The degree to which intraductal carcinoma of the prostate (IDC-P) affects clinical course remains poorly understood owing to small sample sizes from single-center studies. We sought to determine prognostic factors and outcomes associated with IDC-P in radical prostatectomy (RP) specimens.This is a retrospective study of RP during 2004 to 2013 using Surveillance, Epidemiology, and End Results

2017 Urologic oncology

292. Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study Full Text available with Trip Pro

Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study Infiltrating ductal carcinoma (IDC) is a rare histologic subtype of prostate cancer. We investigated the clinicopathological features and prognosis of IDC compared with acinar cell carcinoma (ACC). We identified 3814 men diagnosed with prostate cancer between 2004 to and 2013 in the Surveillance, Epidemiology, and End Results database, including 511 (...) IDC and 3303 ACC cases. Prostate cancer-specific survival (PCSS) was compared using univariate and multivariate Cox proportional hazards models. Generally, IDC occurred in older men (≥ 65 years old) and presented with larger sizes, and higher grades, American Joint Committee on Cancer (AJCC) stages, AJCC T stages, lymph node positive rates and metastasis rates. Men with IDC were less likely to undergo radical prostatectomy, but more likely to be treated with adjuvant radiation than men with ACC

2017 Oncotarget

293. Testicular and Epididymal Metastasis from Prostate Carcinoma: A Rare Manifestation of Common Disease Full Text available with Trip Pro

Testicular and Epididymal Metastasis from Prostate Carcinoma: A Rare Manifestation of Common Disease Carcinoma prostate secondary metastasis to testicle and epididymis is rare. We report a case of metastatic carcinoma prostate in which testicular and epididymal metastasis were diagnosed incidentally in bilateral orchiectomy specimen. Testicular and para testicular structure should be properly evaluated for accurate staging of carcinoma prostate. Epididymis should always be included in bilateral

2017 Journal of clinical and diagnostic research : JCDR

294. Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo Full Text available with Trip Pro

Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo Stromal-epithelial interactions play a crucial and poorly understood role in carcinogenesis and tumor progression. Mesenchymal-epithelial interactions have a long history of research in relation to the development of organs. Models designed to study development are often also applicable to studies of benign and malignant disease. Tumor stroma is a complex mixture of cells that includes (...) of some of these pathways, however the work is still ongoing. This area of research provide a basis for new medical approaches aimed at stabilizing early stage cancers rendering them chronic rather than acute problems. Such work is especially relevant to slow growing tumors found in older patients, a class that would include many prostate cancers.Copyright © 2017 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.

2017 Differentiation; research in biological diversity

295. Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate

, Intraductal, Noninfiltrating Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Breast Carcinoma In Situ Carcinoma in Situ Neoplasms, Ductal, Lobular, and Medullary Docetaxel Abiraterone Acetate Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Steroid Synthesis Inhibitors Enzyme (...) effective for every patient. Also, it's still not clear what's the best therapeutic choice for a certain group of patients. In the previous works of the investigators, a subtype of prostate cancer, intraductal carcinoma of the prostate (IDC-P) was studied. The investigators have reported in their two published papers that, IDC-P is an adverse pathological type associated with rapid disease progression. They also found in another study that, for patients with IDC-P, Abiraterone seemed to have better

2017 Clinical Trials

296. Prognostic significance of E-cadherin expression in prostatic carcinoma: a meta-analysis

Prognostic significance of E-cadherin expression in prostatic carcinoma: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites (...) of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how

2019 PROSPERO

297. Efficacy of denosumab for prevention of skeletal related events in patients with castration sensitive prostate carcinoma

Efficacy of denosumab for prevention of skeletal related events in patients with castration sensitive prostate carcinoma Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

298. Combined, Intensified and Modulated Adjuvant Therapy in Prostate Carcinoma

dose escalation, and selective pelvic irradiation may improve outcome. A phase II trial was designed to prove that combined-intensified-modulated-adjuvant (CIMA) treatment may improve 5-year biochemical relapse free survival (bRFS) from 75% to 90% in high risk patients. The delivered dose to tumor bed and pelvic nodes was 64.8-70.2 Gy and 45 Gy (57% of patients), respectively, and 69% received ADT. Condition or disease Intervention/treatment Phase Prostate Cancer Radiation: Combined, intensified (...) irradiation for patients at risk for regional failures may improve the outcome. The combined-intensified-modulated-adjuvant (CIMA) as described may improve survival through a reduction of loco-regional and systemic failures. A phase II trial was designed to test the hypothesis that CIMA treatment may improve 5-year bRFS by 15%. Patients less than 80 years old, with a histological diagnosis of prostate adenocarcinoma without distant metastases, stage pT2-4 N0-1, no previous treatments and an ECOG

2017 Clinical Trials

299. Prostate-Specific Antigen?Based Population Screening for Prostate Cancer

cancer (PC) is the most commonly diagnosed non-cutaneous cancer in men and their second or third most common cause of cancer-related deaths. Prostate cancer is a heterogeneous disease with a variable natural history ranging from low-risk tumours (unlikely to threaten men’s quality or length of life) to highly aggressive forms. The etiology of PC is largely unknown and the established risk factors—older age, ethnicity, and family history—explain only a fraction of variation in disease occurrence (...) -based screening programs aim to reduce disease-specific mortality and/or morbidity by identifying disease at an early stage when it is more likely to be curable. Prostate-specific antigen (PSA) testing for PC has been common practice for years and the prevalence of self- reported PSA testing in Canadian men is 48%. Screen-detected cases must account for a substantial proportion of disability or death from disease. It is not entirely clear with PC to what extent the early forms of the disease

2015 Health Quality Ontario

300. Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer

. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama. 2005;294(4):433-439. 76. Cox JD, Stoffel TJ. The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate. Cancer. 1977;40(1):156-160. 77. Scardino PT. The prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol. 1983;1(4):243-252. 78. Freiha FS, Bagshaw MA. Carcinoma of the prostate: results of post-irradiation biopsy (...) patients with erectile dysfunction after irradiation for prostate cancer. Supporting Documents ? ACR Appropriateness Criteria ® Overview ? Evidence Table References 1. Hanks GE, Hanlon AL, Schultheiss TE, et al. Conformal external beam treatment of prostate cancer. Urology. 1997;50(1):87-92. 2. Perez CA, Cosmatos D, Garcia DM, Eisbruch A, Poulter CA. Irradiation in relapsing carcinoma of the prostate. Cancer. 1993;71(3 Suppl):1110-1122. 3. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1

2013 American College of Radiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>